Osteoporosis Drugs Market Expected to Reach US$7,342.2 Mn by 2022

Global Market Study on Osteoporosis Drugs: Asia Pacific to Witness Highest Growth by 2022
The global osteoporosis drugs market is witnessing significant growth due to rising geriatric
population and changing lifestyles impinging bone health. Prevalence of osteoporosis is high among
people aged 60 years and above. Moreover, increasing the prevalence of osteoporosis in
postmenopausal women, growing awareness about osteoporotic care, and increasing investment in
drug discovery and development are also driving the growth of the market.
However, there are various side effects and complications associated with osteoporosis drugs such
as heartburn, irritable bowel syndrome, nausea, and ulcers in the stomach or esophagus.
Furthermore, patent expiration of osteoporosis drugs also inhibits the growth of the market.
The osteoporosis drugs market is anticipated to grow from an estimated US$11,226.1 Mn by the
end of 2015 to account for US$14,786.7 Mn by 2022 at a CAGR of 4.0% during the forecast
Request to view table of content @ https://www.persistencemarketresearch.com/marketresearch/osteoporosis-drugs-market/toc
In North America, the prevalence of osteoporosis is high primarily due to increasing geriatric
population, growing obesity, and rising prevalence of lifestyle associated diseases in the region.
According to the National Osteoporosis Foundation, in 2013, approximately 54 million people in
the U.S. aged 50 years and above were affected by osteoporosis and low bone mass. According to
the U.S. Department of Health and Human Services, in the U.S., approximately 250,000 hip
fractures are associated with osteoporosis.
A sample of this report is available upon request @
In Europe, increasing aging population, changing lifestyles, and increasing consumer awareness
about osteoporosis care are driving the growth of the osteoporosis drug market. According to the
International Osteoporosis Foundation, approximately 5.5 million men and 22 million women
suffered from osteoporosis in 2010. Moreover, according to International Osteoporosis Foundation,
approximately 27.5 million people in Europe suffered from osteoporosis in 2010 and the number is
expected to reach 33.9 Mn by 2030.
However, the growth of osteoporosis market in Asia Pacific is much due to rising geriatric
population and changing lifestyles in the region. Osteoporotic patients have a higher risk of hip
fractures, owing to a major cause of morbidity and mortality. According to the International
Osteoporosis Foundation, by 2050, approximately 50% of the world’s osteoporosis hip fractures
would occur in women in Asia. In addition, according to a study on Epidemiology in Osteoporosis
in Japan by the National Centre for Biotechnology Information, in 2011, approximately 15 million
people suffered from osteoporosis in Japan.
Eli Lilly and Company, F. Hoffmann-La Roche, Ltd., Merck & Co. Inc., Novartis AG, Amgen, Inc.,
Actavis plc, Teva Pharmaceuticals Industries Ltd., and Pfizer, Inc. are some of the major players of
osteoporosis drugs market.